Byrd JC et al. Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab. Blood 2019;[Epub ahead of print]. Abstract

Davids MS, Letai A. ABT-199: Taking dead aim at BCL-2. Cancer Cell 2013;23(2):139-41. Abstract

Ding W et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 2017;129(26):3419-27. Abstract

Flinn IW et al. The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood 2018;132(23):2446-55. Abstract

Hallek M et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018;131(25):2745-60. Abstract

Jain N et al. Combined ibrutinib and venetoclax in patients with treatment-naïve high-risk chronic lymphocytic leukemia (CLL). Proc ASH 2018;Abstract 186.

Moreno C et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20(1):43-56. Abstract

O’Brien SM et al. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol 2019;94(5):554-62. Abstract

O’Brien SM et al. Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Proc ASH 2016;Abstract 233.

Seymour JF et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018;378(12):1107-20. Abstract

Shanafelt TD et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): A trial of the ECOG-ACRIN Cancer Research Group (E1912). Proc ASH 2018;Abstract LBA-4.

Stilgenbauer S et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: Results from the full population of a phase II pivotal trial. J Clin Oncol 2018;36(19):1973-80. Abstract

Wierda WG et al. Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). Proc ASCO 2018;Abstract 7502.

Woyach JA et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379(26):2517-28. Abstract

Woyach JA et al. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012;120(6):1175-84. Abstract

Younes A et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: A phase 1/2a study. Lancet Haematol 2019;6(2):e67-78. Abstract